Aurogen Overview

  • Year Founded
  • 1992

Year Founded

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

Aurogen General Information

Description

Developer of technology for making pharmaceutical medicines .The company offers pharmaceutical treatment for diabetic neuropathy.

Contact Information

Website
www.aurogen.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • P.O. Box B
  • 202 Remington Street
  • Fort Collins, CO 80522
  • United States
+1 (970)
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Corporate Office
  • P.O. Box B
  • 202 Remington Street
  • Fort Collins, CO 80522
  • United States
+1 (970)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Aurogen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Out of Business 01-Sep-2007 Completed Out of Business
1. Later Stage VC 01-Dec-2005 Completed Generating Revenue
To view Aurogen’s complete valuation and funding history, request access »

Aurogen Patents

  • 21

    Total Documents Applications and Grants

  • Total Patents Families

  • 7

    Granted

  • 1

    Pending

  • Expiring in next 12 mo

Aurogen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2006315766-B2 Method for treating disease or disorder of adult central nervous system associated with tissue shrinkage or atrophy by administration of insulin Inactive 11-Nov-2005
AU-2006315766-A2 Method for treating disease or disorder of adult central nervous system associated with tissue shrinkage or atrophy by administration of insulin Active 11-Nov-2005
AU-2006315766-A1 Method for treating disease or disorder of adult central nervous system associated with tissue shrinkage or atrophy by administration of insulin Active 11-Nov-2005
CA-2629294-A1 Method for treating disease or disorder of adult central nervous system associated with tissue shrinkage or atrophy by administration of insulin Inactive 11-Nov-2005
EP-1948222-A1 Method for treating disease or disorder of adult central nervous system associated with tissue shrinkage or atrophy by administration of insulin Inactive 11-Nov-2005 A61K38/28
To view Aurogen’s complete patent history, request access »

Ready to get started?

Request a free trial

Aurogen FAQs

  • When was Aurogen founded?

    Aurogen was founded in 1992.

  • Where is Aurogen headquartered?

    Aurogen is headquartered in Fort Collins, CO.

  • What industry is Aurogen in?

    Aurogen’s primary industry is Pharmaceuticals.

  • Is Aurogen a private or public company?

    Aurogen is a Private company.

  • What is Aurogen’s current revenue?

    The current revenue for Aurogen is .

  • How much funding has Aurogen raised over time?

    Aurogen has raised $60K.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »